Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR Exon 20 (Insertion) status confers therapeutic sensitivity to Amivantamab in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
RYBREVANT (amivantamab for injection) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.